Endurobol

Base Information

• Chemical Name: Endurobol
• CAS No.: 317318-70-0
• Deprecated CAS: 813458-54-7
• Molecular Formula: C21H18F3NO3S2
• Molecular Weight: 453.50
• UNII: 7I2HA1NU22
• DSSTox Substance ID: DTXSID3041037
• Nikkaji Number: J1.561.880I
• Wikipedia: GW501516
• Wikidata: Q5515069
• Pharos Ligand ID: JTL59YXYBVHL
• Metabolomics Workbench ID: 66619
• ChEMBL ID: CHEMBL38943
• Mol file: 317318-70-0.mol

Synonyms:cardarine;endurobol;GW 1516;GW 501516;GW-1516;GW-501516;GW1516;GW501516

Chemical Property of Endurobol

Chemical Property:

• Appearance/Colour: white solid
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 134-136°C
• Refractive Index: 1.619
• Boiling Point: 584.543 °C at 760 mmHg
• PKA: 3.17±0.10(Predicted)
• Flash Point: 307.321 °C
• PSA: 112.96000
• Density: 1.426 g/cm³
• LogP: 6.20140
• Storage Temp.: Refrigerator
• Solubility.: DMSO: soluble20mg/mL, clear
• XLogP3: 5.9
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 9
• Rotatable Bond Count: 7
• Exact Mass: 453.06802027
• Heavy Atom Count: 30
• Complexity: 572

Purity/Quality:

99%, ^*data from raw suppliers

GW501516 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
• Recent ClinicalTrials: GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
• Recent EU Clinical Trials: A multicentre, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of once daily oral dosing of GW501516 (2.5 mg, 5 mg and 10 mg) over 12 weeks in subjects with
• Description: GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-δ) agonist. Activation of the receptor will increase fat-burning capacity and muscle production, as it changes the body's fuel preference from glucose to lipids. Peroxisome proliferator-activated receptor δ (PPARδ) stimulation or over-expression in adipocytes leads to increased fatty acid oxidation, improved exercise tolerance, and resistance to obesity. GW 501516 is the first highly selective synthetic PPARδ agonist available. GW 501516 binds to human PPARδ with an IC50 value of 1 nM, and is at least 100-fold selective for PPARδ compared to PPARα and PPARγ. In obese primates, GW 501516 increases high density lipoprotein cholesterol and apolipoprotein A-1 specific reverse cholesterol transport. GW 501516 is therefore a model compound for a new type of obesity therapeutic, as well as a selective pharmacological tool for understanding lipid metabolism.
• Uses: An experimental drug meant to control lipids and increase the level of HDL, or good cholesterol, in the bloodstream. A cell-permeable, thiazolyl compound that acts as a potent, high affinity, PPARd agonist. Exhibits selectivity for PPARd compared t GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model.